Survival analysis of time to reimbursement of novel medicines in five Eurasian countries
{{output}}
Background: Access to novel medications matters quality-adjusted life years and the opportunity cost associated with productivity lost. Gaps in patient access to novel medicines exist due to insufficient public funding reimbursem... ...
